Get the Stockscreener App
1.20
3.23%
-0.04
After Hours:
1.24
0.04
+3.33%
Hoth Therapeutics Inc stock is traded at $1.20, with a volume of 335.54K.
It is down -3.23% in the last 24 hours and up +46.41% over the past month.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
See More
Previous Close:
$1.24
Open:
$1.26
24h Volume:
335.54K
Relative Volume:
0.04
Market Cap:
$8.28M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.9091
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
-6.25%
1M Performance:
+46.41%
6M Performance:
+91.08%
1Y Performance:
-15.46%
1-Day Range:
$1.20
$1.26
1-Week Range:
$1.16
$1.35
52-Week Range:
$0.58
$3.80
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
590 MADISON AVENUE, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
1.20 | 8.28M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal - MSN
Research Analysts Set Expectations for HOTH FY2024 Earnings - Defense World
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at HC Wainwright - Defense World
Hoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsNew York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced today that it has successfully regained compliance with the minimum bid price requirement s - Defense World
Financial Contrast: Hoth Therapeutics (NASDAQ:HOTH) vs. Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Hoth Therapeutics expands cancer drug patent portfolio - MSN
Hoth Therapeutics Breaks New Ground! Nasdaq Compliance Achieved! - Mi Valle
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements - PR Newswire
Hoth Therapeutics expands cancer drug patent portfolio By Investing.com - Investing.com Australia
Hoth Therapeutics Acquires New Patent Applications - Contract Pharma
Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications - PR Newswire
Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 - PR Newswire
Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More - MSN
Shares Of This Micro Cap More Than Doubled Today - MSN
3 Penny Stocks to Watch Now, 1/9/25 - TipRanks
Hoth Therapeutics maintains strong cash position, no offering plans By Investing.com - Investing.com Nigeria
Hoth Therapeutics Shares Recover; Company Has No Plans for Offering - MarketWatch
Hoth Therapeutics maintains strong cash position, no offering plans - Investing.com
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries - PR Newswire
S&P 500 E-Mini (ESM23) Quote - The Globe and Mail
Hoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s Excited - Asianet Newsable
Dow Jones Transportations Average (DOWT) QuotePress Release - The Globe and Mail
Dow Jones Global (DOWG) QuotePress Release - The Globe and Mail
Hoth reports 100% success in cancer skin toxicity trial By Investing.com - Investing.com South Africa
Hoth Therapeutics up over 218% on dermatology breakthrough for cancer patients - Mugglehead
Hoth Therapeutics stock hits 52-week high at $1.73 By Investing.com - Investing.com Australia
S&P 500 ESG (ESG) QuotePress Release - The Globe and Mail
PHLX Euro FX (XDE) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success - Yahoo Finance
Why Hoth Therapeutics Inc Stock Might Make Sense If Bought Today - Stocks Register
Stock market news: Hoth Therapeutics +184.32%, DatChat +79.85% among top gainers during mid day trading - Business Upturn
Stock market news: SPI Energy saw rise of 276.74% while Hoth Therapeutics surged by 186.73% during mid day trading - Business Upturn
Nasdaq Down 1.5%; RPM Posts Upbeat Results - Benzinga
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday? - Benzinga
Hoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer Treatment - MarketWatch
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):